financetom
Business
financetom
/
Business
/
Aeva Technologies supplying sensors for Airbus autonomous gate taxi tests
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Aeva Technologies supplying sensors for Airbus autonomous gate taxi tests
May 26, 2025 10:35 AM

SAN FRANCISCO (Reuters) - Aeva Technologies ( AEVA ) said on Monday it is supplying sensors to a subsidiary of European aircraft manufacturer Airbus that is working to develop planes that can taxi to airport gates autonomously.

Aeva ( AEVA ), founded by former Apple and Nikon engineers, makes a lidar sensor that can map a three-dimensional view of the area around the vehicle and detect how fast distant objects are moving.

It said it is supplying those sensors to Airbus UpNext, which will use the sensors on a testing truck and an A350-1000 flight test aircraft at Toulouse-Blagnac Airport in France.

Aeva ( AEVA ) did not disclose financial details of the deal. Aeva ( AEVA ) CEO Soroush Salehian said the deal will involve several fitting sensors on the initial test plane. 

"We're all working toward automation and this is a new extension for us into aerospace. It's focused on the here and now - improving airport efficiency and reducing the workload on pilots," he told Reuters on Monday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate
Compass Therapeutics Says its Ongoing Biliary Tract Cancer Combination Drug Trial Indicates Statistically Significant Overall Response Rate
Apr 1, 2025
09:03 AM EDT, 04/01/2025 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Tuesday topline data from an ongoing phase 2/3 trial of tovecimig combined with paclitaxel in biliary tract cancer showed 'statistically significant' improvement in overall response rate, indicating it has met the trial's primary efficacy endpoint. The drug combination achieved a 17.1% ORR, including one complete response, versus...
Qualcomm considers takeover offer for UK's Alphawave
Qualcomm considers takeover offer for UK's Alphawave
Apr 1, 2025
April 1 (Reuters) - Chipmaker Qualcomm said on Tuesday it is considering making an offer to acquire UK-based Alphawave IP Group ( AWEVF ). ...
Roblox announces new ad format, Google partnership to boost advertising business
Roblox announces new ad format, Google partnership to boost advertising business
Apr 1, 2025
(Reuters) - Roblox ( RBLX ) on Tuesday launched a new format of video advertising on its gaming platform and announced a partnership with Google to help boost the growth of its nascent ad business. Gamers can choose to watch video advertisement, up to 30 seconds long, in exchange for boosts, lifelines or resources in a particular game through rewarded...
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases
Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases
Apr 1, 2025
09:05 AM EDT, 04/01/2025 (MT Newswires) -- Apellis Pharmaceuticals ( APLS ) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases. The company said the application is based on results from a late-stage trial that...
Copyright 2023-2026 - www.financetom.com All Rights Reserved